CONGENITAL THERAPIES

Harmony™ TPV Innovation Video - (04:47)

Learn how the Harmony™ Transcatheter Pulmonary Valve System was designed specifically for the native Right Ventricular Outflow Tract (RVOT) and the various anatomies.
More information (see more) Less information (see less)

SUNDAY, MAY 16, 2021

3:45-4:15 p.m. EST
Virtual innovation Stage session  

Breakthrough Transcatheter Pulmonary Valve Treatment Option for Adult and Pediatric Congenital Heart Disease Patients

Learn more about Harmony™ Transcatheter Pulmonary Valve (TPV) from Medtronic: the first minimally invasive alternative for patients with severe pulmonary regurgitation who have a native or surgically-repaired right ventricular outflow tract (RVOT) and are clinically indicated for surgical pulmonary valve replacement. Harmony TPV allows a broader range of congenital heart disease patients access to transcatheter technology, thus fulfilling a significant unmet clinical need. This novel therapy recently received FDA approval and is now available for use in the United States.

Presenter: Doff B. McElhinney, M.D., Lucile Packard Children's Hospital at Stanford​

Session Details

pdf Harmony™ TPV Product Brochure (.pdf)

Learn more about the Harmony™ Transcatheter Pulmonary Valve System: The first FDA-approved transcatheter valve system specifically designed to treat severe pulmonary regurgitation — offering Congenital Heart Disease patients a minimally invasive treatment option.

1012KB

pdf Harmony™ TPV Patient Brochure (.pdf)

Informs Congenital Heart Disease patients about the Harmony TPV therapy and its goal to restore pulmonary valve function while delaying the next open-heart surgery.

2.5MB

pdf Melody™ TPV 10-Year Data Sell Sheet (.pdf)

10-year Outcomes in the Original U.S. Investigational Device Exemption Trial Cohort.

396KB

CONTACT

Do you have a question? We’d like to hear from you.

Contact us